New device aims to keep ICU Patients' muscles strong
NCT ID NCT07362862
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests whether a device called MyokinE100, which sends electrical signals to the thigh muscles, is safe and practical for use in the ICU. It includes 50 critically ill patients with sepsis who are at risk of muscle weakness. Half will receive standard care plus daily 60-minute sessions of electrical stimulation, while the other half gets standard care alone. Researchers will monitor for side effects and measure muscle strength changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MyokinE100 electrical muscle stimulation device
What this could lead to
If successful, this device could help ICU patients maintain muscle strength and recover faster, reducing long-term disability.
What could go wrong
This is an early feasibility study with only 50 participants, so results may not apply broadly. The device may cause discomfort or skin irritation, and it is not yet proven to prevent weakness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascension Seton Medical Center Austin
RECRUITINGAustin, Texas, 78705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dell Seton Medical Center at The University of Texas
RECRUITINGAustin, Texas, 78701, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact